Sphingolipid signaling in metabolic disorders

Timothy Hla; Andrew J. Dannenberg

doi:10.1016/j.cmet.2012.06.017

Sphingolipid signaling in metabolic disorders

Timothy Hla, Andrew J. Dannenberg

Academic Institute

Research output: Contribution to journal › Review article › peer-review

229 Scopus citations

Abstract

Sphingolipids, ubiquitous membrane lipids in eukaryotes, carry out a myriad of critical cellular functions. The past two decades have seen significant advances in sphingolipid research, and in 2010 a first sphingolipid receptor modulator was employed as a human therapeutic. Furthermore, cellular signaling mechanisms regulated by sphingolipids are being recognized as critical players in metabolic diseases. This review focuses on recent advances in cellular and physiological mechanisms of sphingolipid regulation and how sphingolipid signaling influences metabolic diseases. Progress in this area may contribute to new understanding and therapeutic options in complex diseases such as atherosclerosis, diabetes, metabolic syndromes, and cancer.

Original language	English (US)
Pages (from-to)	420-434
Number of pages	15
Journal	Cell Metabolism
Volume	16
Issue number	4
DOIs	https://doi.org/10.1016/j.cmet.2012.06.017
State	Published - Oct 3 2012

ASJC Scopus subject areas

Physiology
Molecular Biology
Cell Biology

Access to Document

10.1016/j.cmet.2012.06.017

Cite this

@article{578d22e6dfa040c2bffa956ec7346deb,

title = "Sphingolipid signaling in metabolic disorders",

abstract = "Sphingolipids, ubiquitous membrane lipids in eukaryotes, carry out a myriad of critical cellular functions. The past two decades have seen significant advances in sphingolipid research, and in 2010 a first sphingolipid receptor modulator was employed as a human therapeutic. Furthermore, cellular signaling mechanisms regulated by sphingolipids are being recognized as critical players in metabolic diseases. This review focuses on recent advances in cellular and physiological mechanisms of sphingolipid regulation and how sphingolipid signaling influences metabolic diseases. Progress in this area may contribute to new understanding and therapeutic options in complex diseases such as atherosclerosis, diabetes, metabolic syndromes, and cancer.",

author = "Timothy Hla and Dannenberg, \{Andrew J.\}",

note = "Funding Information: This work is supported by NIH grants (HL49094, HL67330, HL70694, HL89934) to T.H. and NIH grant CA154481, the Breast Cancer Research Foundation, and the Botwinick-Wolfensohn Foundation to A.J.D.",

year = "2012",

month = oct,

day = "3",

doi = "10.1016/j.cmet.2012.06.017",

language = "English (US)",

volume = "16",

pages = "420--434",

journal = "Cell Metabolism",

issn = "1550-4131",

publisher = "Cell Press",

number = "4",

}

TY - JOUR

T1 - Sphingolipid signaling in metabolic disorders

AU - Hla, Timothy

AU - Dannenberg, Andrew J.

N1 - Funding Information: This work is supported by NIH grants (HL49094, HL67330, HL70694, HL89934) to T.H. and NIH grant CA154481, the Breast Cancer Research Foundation, and the Botwinick-Wolfensohn Foundation to A.J.D.

PY - 2012/10/3

Y1 - 2012/10/3

N2 - Sphingolipids, ubiquitous membrane lipids in eukaryotes, carry out a myriad of critical cellular functions. The past two decades have seen significant advances in sphingolipid research, and in 2010 a first sphingolipid receptor modulator was employed as a human therapeutic. Furthermore, cellular signaling mechanisms regulated by sphingolipids are being recognized as critical players in metabolic diseases. This review focuses on recent advances in cellular and physiological mechanisms of sphingolipid regulation and how sphingolipid signaling influences metabolic diseases. Progress in this area may contribute to new understanding and therapeutic options in complex diseases such as atherosclerosis, diabetes, metabolic syndromes, and cancer.

AB - Sphingolipids, ubiquitous membrane lipids in eukaryotes, carry out a myriad of critical cellular functions. The past two decades have seen significant advances in sphingolipid research, and in 2010 a first sphingolipid receptor modulator was employed as a human therapeutic. Furthermore, cellular signaling mechanisms regulated by sphingolipids are being recognized as critical players in metabolic diseases. This review focuses on recent advances in cellular and physiological mechanisms of sphingolipid regulation and how sphingolipid signaling influences metabolic diseases. Progress in this area may contribute to new understanding and therapeutic options in complex diseases such as atherosclerosis, diabetes, metabolic syndromes, and cancer.

UR - https://www.scopus.com/pages/publications/84867096429

UR - https://www.scopus.com/inward/citedby.url?scp=84867096429&partnerID=8YFLogxK

U2 - 10.1016/j.cmet.2012.06.017

DO - 10.1016/j.cmet.2012.06.017

M3 - Review article

C2 - 22982021

AN - SCOPUS:84867096429

SN - 1550-4131

VL - 16

SP - 420

EP - 434

JO - Cell Metabolism

JF - Cell Metabolism

IS - 4

ER -

Sphingolipid signaling in metabolic disorders

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this